In the last two years, the FDA has approved four drugs in the SGLT-2 inhibitors class: canagliflozin (brand name Invokana, Jansssen), dapagliflozin (brand name Farxiga, AstraZeneca), empagliflozin (brand name Jardiance, Boehringer Ingelheim), and ertugliflozin (brand name Steglatro, Merck/Pfizer). What is important for doctors to know about these new drugs, and how they should be prescribed? Read more